Trending...
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- School Dental Screening Programs Conducted in Dubai
- Looking for expert pool tiling in Gold Coast? Call Avid Tiling
WATERTOWN, Mass., June 18, 2024 ~ Remix Therapeutics, a clinical-stage biotechnology company, has recently announced the appointment of Dr. Maria Koehler as an independent director to their Board of Directors. This move comes as Remix continues to develop small molecule therapies that target RNA processing and address the underlying causes of various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
- STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
- West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
- CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
- Brilliant Minds to Gather in Fort Worth for National Mensa Event
- UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
Filed Under: Business
0 Comments
Latest on The PennZone
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
- Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
- Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
- What Would you Do with Your Time if it Was Actually Money?
- Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
- Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
- Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
- Appliance EMT Launches June "Summer Rescue" Promotion
- New Luxury Single Family Homes From $976,990 in Manalapan
- Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
- Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
- K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
- HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
- KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
- School Dental Screening Programs Conducted in Dubai
- British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally